HEALTH TECHNOLOGY

Novarad Releases Web Version of Its Medical Image Sharing System, CyrptoChartTM

Novarad Corporation | June 02, 2022

Novarad Releases

The Industry leader in medical imaging technologies, Novorad, announced the release of a web-only version of CryptoChartTM, a cutting-edge medical imaging system that offers secure storage and transfer of digital health records through encrypted QR and web access codes. 

The Lite version of CryptoChartTM will be available at no extra cost, empowering patients and their providers with a seamless experience. Transparent and complete access to medical imaging technology. This will also eliminate accessibility concerns regardless of the geographical setting.

"One of the recurring frustrations by providers and patients alike is sharing information from different facilities while maintaining strict privacy. Being able to send large digital files like medical images quickly with a built-in viewer anywhere in the world helps simplify access, improve patient outcomes, and lower the cost of providing world-class care anywhere."

David GrandPre, Sr. Director of Product, Novarad

CryptoChartTM Lite instantly addresses the challenge of isolated systems and delivers a streamlined access to medical reports and imaging without the use of portals or login information. The information, URL, and passwords are embedded into an ultra-secure, optically readable, and shareable QR code. 

"The CryptoChart Lite service is exactly the prescription needed for healthcare professionals frustrated by the barriers of accessing medical images. It's like a medical Dropbox. Technology should make it easier to provide patient care, not get in our way. The Lite version allows facilities globally to try out the CryptoChart platform. We've made it easy with no sign-up required. Just drag and drop the file." Dr. Wendell Gibby, Founder and CEO, Novarad
 

Spotlight

In May 2014, NHS England invited CCGs to come forward with expressions of interest to take on an increased role in the commissioning of primary care services. The intention was to empower and enable CCGs to improve primary care services locally for the benefit of patients and local communities. The scope of primary care co-commissioning for 2015/16 was primary medical services only.

Spotlight

In May 2014, NHS England invited CCGs to come forward with expressions of interest to take on an increased role in the commissioning of primary care services. The intention was to empower and enable CCGs to improve primary care services locally for the benefit of patients and local communities. The scope of primary care co-commissioning for 2015/16 was primary medical services only.

Related News

HEALTH TECHNOLOGY

Medical Device Innovation Consortium Launches Initiative to Improve Accuracy of Next Generation Sequencing-Based Cancer Diagnostics

MDIC | August 23, 2022

The Medical Device Innovation Consortium formally launched its Somatic Reference Samples Initiative with a pilot project to improve the validation and regulatory review process for cancer diagnostics based on next generation sequencing. MDIC will lead a collaboration with the U.S. Food and Drug Administration the National Institute of Standards and Technology, National Institutes of Health and industry stakeholders to manufacture, validate, and distribute SRSs to simplify and support validation of NGS-based cancer diagnostics. The initiative also includes the goal to create a publicly available global genomic data resource library of datasets with the potential to be used by sponsors and regulators. “NGS is a powerful technology enabling breakthroughs in diagnostics and ultimately therapeutics. These diagnostic tests need to be validated for accurate clinical use, and reference samples are essential to the validation process. But well-characterized and widely accepted reference materials do not exist for NGS-based diagnostics, complicating the development and validation process. Through the MDIC SRS Initiative, we are developing reference samples and data sets that can be used globally by test developers and regulators to bring more consistency to NGS-based cancer diagnostic development, increasing the confidence and accuracy of these tests, which will ultimately lead to more accuracy in diagnosis and treatment for patients.” Andrew Fish, President and CEO, MDIC “There is a need for appropriately consented, highly characterized, and broadly available reference materials that may improve the accuracy, reliability, and transparency of NGS-based oncology tests and support the generation of validation data for use in regulatory submissions. The reference samples and datasets being created by the MDIC Somatic Reference Samples Initiative can help fulfill this need,” said Wendy Rubinstein, MD, PhD, Director, Personalized Medicine, Center for Devices and Radiological Health, U.S. Food and Drug Administration. Horizon Discovery, a PerkinElmer company, is conducting the development and manufacture of these reference samples. The goal of this pilot project is to individually engineer 10 gene variants clinically associated with cancer into a highly characterized human cell line – GM24385 using Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) technology resulting in ten edited human cell lines, each containing one gene variant clinically associated with one or more specific cancers. The cell lines, containing confirmed sequences, will be combined and available in FFPE format. The fully characterized reference samples will be commercially available to the end users from Horizon and the characterization data will be accessible through public databases, including precisionFDA, an FDA-sponsored site for data information, sequencing, and bioinformatics. NIST’s involvement in this work is to foster understanding.* “As our collaboration validates the MDIC SRS samples, we will also learn and build best practices to improve the efficiency and sustainability of reference sample validation and dataset generation in general. This project is a major step in the development and optimization of new sequencing technologies and the translation of DNA sequencing to clinical applications for diagnosing and treating cancer,” said Justin Zook, PhD, Co-Leader, Biomarker and Genomic Sciences Group, National Institute of Standards and Technology. MDIC’s SRS project began as a working group in 2018, representing more than forty stakeholders with a mission to address the gap in reference material for NGS-based diagnostic tests. The initial output of this working group, MDIC’s SRS Landscape Analysis, published in 2019, was a comprehensive catalog of existing clinically relevant cancer variants and available reference samples. Based on the unmet needs discovered through the SRS Landscape Analysis, the SRS Initiative has prioritized a subset of ten variants to be engineered into reference samples for the pilot project. In addition to the utility of these samples in development, validation, and regulatory review, these samples potentially have value in reimbursement decisions, post-market monitoring and informing the path forward for addition SRS. The work in the SRS Initiative is funded in part by the Gordon and Betty Moore Foundation the National Philanthropic Trust, Illumina, and Quidel. Affiliation with a commercial product does not imply recommendation or endorsement by the National Institute of Standards and Technology, nor does it imply that the materials or equipment identified are necessarily the best available for the purpose. About MDIC Founded in 2012, the Medical Device Innovation Consortium is the first public-private partnership created with the sole objective of advancing medical device regulatory science throughout the total product life cycle. MDIC’s mission is to transform health care into human care. Collaborating with our partners to advance science, we enable transformational medical technology to shape the world we want to live in and make that world possible by shortening the path from innovation to safety to access.

Read More

HEALTH TECHNOLOGY

Sonde Health Inks MultiYear Partnership with Koye Pharmaceuticals

Sonde Health | August 25, 2022

Sonde Health, a leading enterprise vocal biomarker company, has signed a multi-year agreement with Koye Pharmaceuticals, a specialty pharma organization focused on the Indian Pharmaceutical market, to develop a new vocal biomarker detection and monitoring capability for chronic obstructive pulmonary disease in India. This deal represents Sonde’s first partnership with a pharmaceutical company. As part of this arrangement, Koye will leverage Sonde’s vocal biomarker development (VBD) platform, expanding upon its already existing respiratory responsive vocal biomarker, to create an entirely novel vocal biomarker for COPD in India. This will allow Koye to develop solutions that help track and treat respiratory health in COPD patients using their voice. “This collaboration marks a major milestone in Sonde Health’s growth and evolution, and we’re excited to take this step with Koye Pharmaceuticals. Partnering directly with pharmaceutical companies allows them to take a more targeted and engaging approach with prospective patients, aligning their needs with the most impactful therapeutics. While there’s no cure for COPD, this new vocal biomarker will allow physicians to better manage their patients’ symptoms using early monitoring and constant engagement to ensure those impacted by COPD get on the right treatment plans early and often.” David Liu, CEO of Sonde Health COPD, a chronic inflammatory lung disease that creates airflow blockage and makes it difficult to breathe, is the third leading cause of death worldwide – causing 3.23 million deaths in 2019, according to the World Health Organization – and the second highest cause of death and disability in adjusted life years (DALYs) in India after heart disease, per the University of Washington’s Global Burden of Disease study. As of 2018, India had 18% of the world’s population, but 32% of the COPD cases. COPD was responsible for 13% of all deaths in India. A worldwide study has estimated that India’s death rate from COPD during 2019 was 98 per 100,000 population, three times the American rate of 33 and the British rate of 31. According to the latest figures, India has an estimated 50 million people living with COPD. “We have been keen on utilizing an accessible platform with digital biomarkers that will both aid physicians in identifying and understanding their patients’ conditions better and also make it easier for patients with chronic respiratory conditions to monitor their health in the least invasive way possible. This partnership with Sonde Health is exactly what we were looking for,” said Preetish Toraskar, Founder and Director at Koye Pharmaceuticals. “Not only is Sonde at the forefront of vocal biomarker technology, but their extensive experience in respiratory health will prove invaluable as we work to get this debilitating condition under control in India.” Sonde Health has previously developed and commercialized vocal biomarker technology to detect and monitor respiratory impairment. In early 2022, the company partnered with GN Group, a leading global manufacturer of hearing instruments and audiological diagnostics equipment and headsets, to create vocal biomarker technology to detect Mild Cognitive Impairment. About Sonde Health Sonde Health has developed an enterprise vocal biomarker platform that enables any company to either license respiratory or mental fitness monitoring product or create a novel vocal biomarker product. Sonde scales data collection, feature development, model creation and clinical validation in collaboration with its partners and customers. Leveraging over 1 million voice samples from 80,000+ individuals, Sonde uses advanced audio signal processing and machine learning to sense and analyze subtle vocal changes due to changes in a person’s physiology to provide key insights into health and well-being. About Koye Pharmaceuticals Koye Pharmaceuticals Pvt. Ltd. was founded in 2013 by two experienced professionals of the pharma industry, Mr. Preetish Toraskar and Mr. Ravindra Shenoy. Since its foundation, Koye has expanded its operations to run across the length and breadth of the country aided by their strong distribution network. Koye today has more than 1250+ qualified ambassadors who meet up with more than 100,000+ doctors across the country every month. The company which believes in pursuing 'healthiness' has a strong foothold in different therapeutic segments that include state-of-the-art products in Specialty Primary Care, Respiratory, Gynaecology, IVF and Cardio-Diabetic segments.

Read More

HEALTH TECHNOLOGY

Kaia Health Raises the Bar for Automated Mobility Assessments with Launch of 3D Computer-Vision MSK Solution

Kaia Health | August 19, 2022

Kaia Health, the largest global digital therapeutics company on a mission to deliver the most effective digital therapies – anytime, anywhere, announced the addition of 3D full body mobility assessments, raising the bar for the standard of care delivery with motion analysis technology. The technology creates a full 3D model of the body, removing the need for restrictive placement of the phone, and tracks the most important skeletal structures with an eye to what clinical teams care about most and with unparalleled precision. Tracking the most relevant points of any company in the world with high precision, allows continuous detection of subtle displacements and mobility limitations in the back, hip, knee, and ankles, something that neither in-person physical therapy or other virtual options can achieve. Using only a smartphone or tablet, there is no need for sensors or additional devices. Using this quantitative data, members are provided with a personalized physical therapy program, real-time feedback, and specific exercises to help counteract mobility limitations. The technology also enables improved care design by the care team, a better understanding of the member’s progression over time, and as a result, improved clinical outcomes. “With this new capability, we are able to deliver the most effective digital therapy experience by analyzing movement in real-time and providing a tailored program for each of our members. We are proud to be a world-leader in improving access to great care by delivering this innovative, clinically-validated solution to our members, driving better clinical outcomes and an optimal ROI at scale for our health plan and employer partners.” Simon Hayhurst, chief product officer of Kaia Health The global market for computer vision applied to healthcare is expected to reach $5.15 billion by 20261, and in recent months, the technology has seen rapid adoption among companies that provide MSK solutions. Kaia Health is a pioneer in MSK technology and computer vision, having introduced it in 2018 with their exercise feedback and assessments capabilities. A study published in the peer-reviewed Journal of Medical Internet Research previously demonstrated Kaia Health’s technology to be as accurate as a physical therapist in suggesting exercise corrections. About Kaia Health Kaia Health is the world’s largest digital therapeutics company on a mission to empower millions of people to live their healthiest life. Our evidence-based treatments, covering a range of conditions, including musculoskeletal pain and COPD, are powered by proprietary motion analysis technology and clinical expertise. No sensors or wearables, Kaia’s programs need only a smartphone to deliver the most accessible, effective, and equitable experience for all. Eleven randomized clinical trials have shown Kaia’s effectiveness and safety to be as good as traditional care with up to 80% reduction in cost. Kaia Health is a member of the Digital Therapeutics Alliance (DTA) and is headquartered in NY and Munich. Kaia partners with leading health plans, employers, and providers, covering 60+ million lives around the world.

Read More